NASDAQ:STOK

Stoke Therapeutics - STOK Stock Forecast, Price & News

$8.03

+0.05 (+0.63%)

(As of 03/28/2023 12:00 AM ET)

Add

Compare

Today's Range: $7.93
▼
$8.13
50-Day Range: $7.65
▼
$9.98
52-Week Range: $6.88
▼
$24.97

Volume: 113,429 shs
Average Volume: 346,014 shs
Market Capitalization: $354.52 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $24.57

Institutional Ownership

Stoke Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.71 Rating Score
Upside/Downside: 206.0% Upside
$24.57 Price Target
Short Interest: Bearish
14.71% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.59
Upright™ Environmental Score
News Sentiment: 0.94
Based on 3 Articles This Week
Insider Trading: Selling Shares
$97,205 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.85) to ($3.14) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

416th out of 1,002 stocks

Pharmaceutical Preparations Industry

192nd out of 488 stocks

4.4

Analyst's Opinion

Consensus Rating
Stoke Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 6 buy ratings, no hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $24.57, Stoke Therapeutics has a forecasted upside of 206.0% from its current price of $8.03.
Amount of Analyst Coverage
Stoke Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

0.0

Short Interest

Percentage of Shares Shorted
14.71% of the float of Stoke Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Stoke Therapeutics has a short interest ratio ("days to cover") of 12, which indicates bearish sentiment.
Change versus previous month
Short interest in Stoke Therapeutics has recently increased by 1.29%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Stoke Therapeutics does not currently pay a dividend.
Dividend Growth
Stoke Therapeutics does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Stoke Therapeutics has received a 77.13% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Stoke Therapeutics is -0.59.

2.7

News and Social Media Coverage

News Sentiment
Stoke Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Stoke Therapeutics this week, compared to 2 articles on an average week.
MarketBeat Follows
Only 3 people have added Stoke Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Stoke Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $97,205.00 in company stock.
Percentage Held by Insiders
12.70% of the stock of Stoke Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Stoke Therapeutics are expected to decrease in the coming year, from ($2.85) to ($3.14) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Stoke Therapeutics is -3.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Stoke Therapeutics is -3.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Stoke Therapeutics has a P/B Ratio of 1.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Stoke Therapeutics (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

Receive STOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

STOK Stock News Headlines

March 28, 2023 | finance.yahoo.com

Investors in Stoke Therapeutics (NASDAQ:STOK) have unfortunately lost 64% over the last three years

March 23, 2023 | americanbankingnews.com

Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of "Moderate Buy" from Brokerages

March 28, 2023 | Weiss Ratings (Ad)

Banking Nightmare

During and after the Great Financial Crisis of 2008, 485 U.S. banks went under. Here at Weiss Ratings, we warned about 484 — an accuracy rate of 99.8%. Now, we have a new warning. But this time, it's not just about a few hundred banks … it's about nearly every single bank in America …

March 17, 2023 | markets.businessinsider.com

Bank of America Securities Remains a Sell on Stoke Therapeutics (STOK)

March 15, 2023 | seekingalpha.com

Stoke gets FDA nod to use higher dose of epilepsy drug in ongoing trial

March 15, 2023 | finance.yahoo.com

Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome

March 9, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (SAGE) and Stoke Therapeutics (STOK)

March 8, 2023 | msn.com

6 Analysts Have This to Say About Stoke Therapeutics

March 28, 2023 | Weiss Ratings (Ad)

Fed's Shocking New Plan to Control Your Money

The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 

March 7, 2023 | msn.com

Credit Suisse Maintains Outperform Rating for Stoke Therapeutics: Here's What You Need To Know

March 6, 2023 | benzinga.com

Stoke Therapeutics Had $230.2M In Cash, Cash Equivalents, Marketable Securities & Restricted Cash, With Cash Runway Extended To The End Of 2025

March 6, 2023 | finance.yahoo.com

Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates

February 27, 2023 | finance.yahoo.com

Stoke Therapeutics to Participate at Upcoming March Investor Conferences

February 7, 2023 | finance.yahoo.com

Stoke Therapeutics to Present at the SVB Securities Global Biopharma Conference

January 26, 2023 | finance.yahoo.com

Companies Like Stoke Therapeutics (NASDAQ:STOK) Can Afford To Invest In Growth

January 11, 2023 | markets.businessinsider.com

Expert Ratings for Stoke Therapeutics

January 9, 2023 | finance.yahoo.com

Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2023

January 4, 2023 | finance.yahoo.com

Stoke Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

December 28, 2022 | seekingalpha.com

STOK Stoke Therapeutics, Inc.

December 26, 2022 | msn.com

Stoke Therapeutics Earnings Perspective: Return On Capital Employed

December 2, 2022 | finance.yahoo.com

Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting

November 29, 2022 | finance.yahoo.com

Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2022 Annual Meeting

November 28, 2022 | seekingalpha.com

Buy Stoke Therapeutics At A Deep Discount Following Early Data In Dravet Syndrome

November 15, 2022 | marketwatch.com

Stoke Therapeutics Down 26% After Reporting STK-001 Data, 3Q Results

November 15, 2022 | seekingalpha.com

Stoke Therapeutics drops 27% after early data for anti-seizure medicine

November 15, 2022 | finance.yahoo.com

Stoke Therapeutics Stock Falls Post Early Efficacy Data From Lead Dravet Syndrome Program

November 14, 2022 | finance.yahoo.com

Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive STOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

STOK Company Calendar

Last Earnings: 3/06/2023
Today: 3/28/2023
Next Earnings (Estimated): 5/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:STOK
CUSIP: N/A
CIK: 1623526
Web: www.stoketherapeutics.com
Phone: (781) 430-8200
Fax: N/A
Employees: 102
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $24.57
High Stock Price Forecast: $35.00
Low Stock Price Forecast: $9.00
Forecasted Upside/Downside: +206.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.71
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.60)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-101,070,000.00
Net Margins: -814.73%
Pretax Margin: -814.73%
Return on Equity: -47.38%
Return on Assets: -35.12%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.77
Quick Ratio: 7.77

Sales & Book Value

Annual Sales: $12.40 million
Price / Sales: 28.56
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.69 per share
Price / Book: 1.71

Miscellaneous

Outstanding Shares: 44,150,000
Free Float: 38,541,000
Market Cap: $354.08 million
Optionable: Not Optionable
Beta: 0.42

Key Executives

Edward M. Kaye
Chief Executive Officer & Director

Huw M. Nash
Chief Operating & Business Officer

Stephen J. Tulipano
Chief Financial Officer

Barry S. Ticho
Chief Medical Officer

Isabel Aznarez
Group Vice President-Discovery Research

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

STOK Stock - Frequently Asked Questions

Should I buy or sell Stoke Therapeutics stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last twelve months. There are currently 1 sell rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" STOK shares.
View STOK analyst ratings or view top-rated stocks.
What is Stoke Therapeutics' stock price forecast for 2023?: 7 brokers have issued 1 year price objectives for Stoke Therapeutics' stock. Their STOK share price forecasts range from $9.00 to $35.00. On average, they expect the company's share price to reach $24.57 in the next twelve months. This suggests a possible upside of 206.4% from the stock's current price.
View analysts price targets for STOK or view top-rated stocks among Wall Street analysts.
How have STOK shares performed in 2023?: Stoke Therapeutics' stock was trading at $9.23 at the start of the year. Since then, STOK stock has decreased by 13.1% and is now trading at $8.02.
View the best growth stocks for 2023 here.
When is Stoke Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our STOK earnings forecast.
How were Stoke Therapeutics' earnings last quarter?: Stoke Therapeutics, Inc. (NASDAQ:STOK) posted its quarterly earnings results on Monday, March, 6th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.71) by $0.06. The business earned $3.27 million during the quarter, compared to the consensus estimate of $2.93 million. Stoke Therapeutics had a negative trailing twelve-month return on equity of 47.38% and a negative net margin of 814.73%.
What ETFs hold Stoke Therapeutics' stock?: ETFs with the largest weight of Stoke Therapeutics (NASDAQ:STOK) stock in their portfolio include Direxion mRNA ETF (MSGR), Virtus LifeSci Biotech Clinical Trials ETF (BBC), WisdomTree BioRevolution Fund (WDNA), Global X Genomics & Biotechnology ETF (GNOM), ALPS Medical Breakthroughs ETF (SBIO) and Principal Healthcare Innovators ETF (BTEC).
What other stocks do shareholders of Stoke Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Gossamer Bio (GOSS), Editas Medicine (EDIT), Alector (ALEC), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Precision BioSciences (DTIL), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), Marvell Technology (MRVL) and Invitae (NVTA).

When did Stoke Therapeutics IPO?: (STOK) raised $100 million in an IPO on Wednesday, June 19th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity was co-manager.
What is Stoke Therapeutics' stock symbol?: Stoke Therapeutics trades on the NASDAQ under the ticker symbol "STOK."
Who are Stoke Therapeutics' major shareholders?: Stoke Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Morgan Stanley (6.22%), Cowen AND Company LLC (1.90%), Deutsche Bank AG (1.90%), Granahan Investment Management LLC (1.40%), M28 Capital Management LP (1.22%) and Geode Capital Management LLC (1.20%). Insiders that own company stock include Apple Tree Partners Iv, LP, Arthur Tzianabos, Barry Ticho, Edward M Md Kaye, Gene Liau, Huw M Nash, Huw M Nash, Robin A Walker and Stephen J Tulipano.
View institutional ownership trends.
How do I buy shares of Stoke Therapeutics?: Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Stoke Therapeutics' stock price today?: One share of STOK stock can currently be purchased for approximately $8.02.
How much money does Stoke Therapeutics make?: Stoke Therapeutics (NASDAQ:STOK) has a market capitalization of $354.08 million and generates $12.40 million in revenue each year. The company earns $-101,070,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis.
How many employees does Stoke Therapeutics have?: The company employs 102 workers across the globe.
How can I contact Stoke Therapeutics?: Stoke Therapeutics' mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The official website for the company is www.stoketherapeutics.com. The company can be reached via phone at (781) 430-8200 or via email at ir@stoketherapeutics.com.

This page (NASDAQ:STOK) was last updated on 3/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Stoke Therapeutics - STOK Stock Forecast, Price & News

Stoke Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Stoke Therapeutics (NASDAQ:STOK) Stock

STOK Stock News Headlines

STOK Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

STOK Stock - Frequently Asked Questions

Overall MarketRank^™